Clover Biopharmaceuticals
Clover Biopharmaceuticals, a leading biopharmaceutical company headquartered in China, is at the forefront of innovative vaccine development and advanced therapeutics. Founded in 2016, Clover has rapidly established itself within the biotechnology industry, focusing on the design and manufacture of protein-based vaccines and biologics. With a strong emphasis on research and development, Clover's core products include its proprietary COVID-19 vaccine candidate, SCB-2019, which has garnered significant attention for its unique protein subunit technology. The company has achieved notable milestones, including successful clinical trials and partnerships that enhance its market position. As a key player in the global biopharmaceutical landscape, Clover Biopharmaceuticals continues to drive advancements in healthcare, aiming to address critical public health challenges.
DitchCarbon Score
How does Clover Biopharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Clover Biopharmaceuticals's score of 7 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Clover Biopharmaceuticals's reported carbon emissions
In 2023, Clover Biopharmaceuticals reported total carbon emissions of approximately 18,092,580 kg CO2e, comprising about 12,570 kg CO2e from Scope 1 and about 18,080,010 kg CO2e from Scope 2 emissions. This represents a slight decrease from 2022, where total emissions were approximately 19,430,860 kg CO2e, with Scope 1 emissions at about 7,950 kg CO2e and Scope 2 emissions at about 19,422,910 kg CO2e. In 2021, the company recorded total emissions of approximately 17,901,210 kg CO2e, with Scope 1 emissions at about 9,320 kg CO2e and Scope 2 emissions at about 17,891,900 kg CO2e. Despite these figures, Clover Biopharmaceuticals has not publicly disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented reduction commitments suggests that the company may be in the early stages of developing a comprehensive climate strategy. As the biopharmaceutical industry increasingly prioritises sustainability, Clover's future climate commitments will be crucial in aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 9,320 | 0,000 | 00,000 |
| Scope 2 | 17,891,900 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Clover Biopharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
